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ABSTRACT 
 
Mississippi Pharmacists’ Perceptions and Knowledge of ADHD in Children 
 
Attention-deficit/hyperactivity disorder (ADHD) is a condition that has garnered 
more attention in the profession of pharmacy in recent years as a result of being more 
commonly diagnosed in both adult and pediatric populations. With new medications 
available, pharmacists need to be knowledgeable about how these products may affect 
patients, especially children. It is crucial to understand pharmacists’ perceptions and 
knowledge of ADHD and its treatments to optimize their provision of treatment for these 
patients. Due to the lack of literature dedicated to pharmacists’ knowledge, familiarity, 
confidence, and perceptions as it relates the condition of ADHD and its treatments, the 
objectives of this study are to measure community pharmacists’ knowledge of, familiarity 
with, confidence in counseling for, and perceptions of, ADHD and associated treatments 
for children. The study objectives were met by employing a descriptive, cross-sectional 
design. Responses were generated using a self-administered survey that was distributed 
electronically to Mississippi pharmacists using Qualtrics Survey Software. The results of 
this study demonstrate that Mississippi pharmacists are generally knowledgeable and 
comfortable in their role as dispensers of ADHD medications for children and also in 
counseling patients and families about those medications. However, there still appears to 
be some need for supplemental education in the form of continuing education or 
enhanced pharmacy school education to reinforce pharmacists’ knowledge about 
pharmacological treatments. Pharmacists were less knowledgeable and familiar with 
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diagnosis of ADHD and non-pharmacological treatments, which is expected given their 
practice area. The question to be asked is whether education for pharmacists in these 
latter areas is necessary, especially if they are not specialists in ADHD. It can be argued 
that pharmacists would benefit from training in ADHD outside of pharmacological 
treatments. As the most accessible healthcare professional, pharmacists are likely to be 
called on by families of patients with ADHD for guidance. Additionally, a collaborative 
healthcare team approach should be taken between doctor, pharmacist, and therapist to 
ensure the patient’s ADHD is not only being handled through medication therapy, but 
through a holistic approach.  
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BACKGROUND 
Description of the Problem 
5.4 million children between the ages of 4 and 17 have been diagnosed with it as 
of 2007, and 2.7 million are receiving medical therapy due to it. Boys are almost three 
times more likely to have it than girls, but only 3-7% of school aged children have it 
(ADHD Data and Statistics in the USA). Attention Deficit Hyperactivity Disorder 
(ADHD) is an ever-present diagnosis on the rise in the minds of Americans. Over the last 
two decades, this disorder has grown from unknown to colloquial language throughout 
various communities, especially academic. In the United States, the western states have 
almost a ten-fold decrease in ADHD rates compared to the midwestern states; which 
include some of the highest with Kentucky at a 14.8% ADHD rate (ADHD by the 
Numbers: Facts, Statistics, and You).  
Across all disciplines, the Centers for Disease Control (CDC) reports that 11% of 
American children have ADHD, a 42% increase in just a short eight years from 2003-
2011 (ADHD by the Numbers: Facts, Statistics, and You). According to post-doctoral 
fellow Meg Reuland who works at the Judge Baker Children’s Center in Boston, 
Massachusetts, young women are less represented in the diagnosis of ADHD due to the 
premise that young girls tend to show the inattentive symptoms of ADHD, as opposed to 
the obvious hyperactive symptoms more typically displayed in boys with ADHD. The 
inattentive symptoms go unnoticed because it appears that the girl is disinterested and 
spacey and not symptomatic of ADHD (Interview with Meg Reuland). The disorder is 
diagnosed far and wide not only across the United States, but also in European countries 
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and even Australia. The numbers will only continue to rise as more awareness and 
education is developed.  
One in five American children diagnosed and living with ADHD is not receiving 
medicine or behavioral therapy for the condition. The medicinal therapy rates vary across 
the country with Louisiana, Kentucky, Indiana, Arkansas, North Carolina, and Iowa 
having the highest rates. Nevada, Hawaii, California, Alaska, New Jersey, Utah, and 
Colorado had the lowest rates of medicinal treatment (ADHD by the Numbers: Facts, 
Statistics, and You). Depending on the child’s age and gender, the implementation of 
medication therapy varies. Children on the upper end of the age spectrum from around 
age 11-17 were more likely to be placed on medicine than those children in younger ages 
from 4-10. In addition, boys were more likely to be placed in medicinal treatment than 
women (ADHD Data and Statistics in the USA). Medicine is not the only route of 
treatment for ADHD patients, and many can be involved in behavioral therapy 
treatments.  
Whether the patient undergoes medicinal or behavioral therapy, the diagnosis and 
treatment of ADHD is a burden not only to the family of the patient, but also to the 
country as a whole. The average yearly cost in total for an ADHD patient is $14,576, and 
$42.5 billion for Americans in general (ADHD by the Numbers: Facts, Statistics, and 
You). The expenses come from not only the treatment of the patient, but also the 
potential costs, such as crime, losing a job, and educational burdens that might arise.  
 
 
 
	 	 	3	
ADHD Symptoms and Diagnosis 
As ADHD flows through the minds of people, especially parents and teachers, the 
activities and engagement by children is under intense scrutiny. Every class, the teacher 
analyzes his or her students looking to see if they are well behaved or if they fidget, 
interrupt, and in general cannot sit still. The parent looks on to see if his or her child is 
able to sit and focus to study for a test or to complete homework. Anything out of the 
ordinary for the child is then explained as a possible symptom of ADHD. It is difficult, 
however, to determine the appropriate level of activity for a child and whether there is an 
appropriate base-rate for comparison. The Diagnostic Statistical Manual (DSM) attempts 
to develop this base-rate and depict a picture of what an ADHD patient is. Through the 
DSM, there is a list of symptoms and personality manifestations that indicate if a person 
or child has ADHD. In order for a child to be classified as having ADHD, the patient 
must exhibit at least six of the explicitly designated symptoms from an inattention group 
of criteria and/or the hyperactivity and impulsivity criteria (ADHD Fact Sheet). The 
symptoms must be present for at least six months and they must involve being 
inappropriate for the developmental level of the patient (Symptoms and Diagnosis). The 
list of the explicit behaviors indicating ADHD is provided in Tables 1 and 2 (Symptoms 
and Diagnosis). 
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Table 1: Inattention Symptoms of ADHD 
 
1: Often fails to give attention to details or makes carless mistakes in school work, work, 
and/or other activities 
2: Trouble holding attention on tasks 
3: Does not listen when spoken to directly 
4: Does not follow through on instructions and fails to finish work 
5: Trouble organizing tasks and activities 
6: Avoids, dislikes, or is reluctant to do tasks that use mental effort over a long period of 
time 
7: Loses things that are necessary for a task or activity 
8: Often easily distracted 
9: Often forgetful in everyday activities 
 
Table 2: Hyperactivity and Impulsivity Symptoms of ADHD 
 
1: Fidgets with or taps hands or feet and squirms in seat 
2: Leaves seat when expected to stay in the seat 
3: Runs or climbs when inappropriate in situation 
4: Unable to play or participate in calm activities quietly 
5: “On the go” constantly 
6:  Talks excessively 
7:  Blurts out an answer before prompted to 
8: Trouble waiting his or her turn 
9: Interrupts or intrudes on others around him or her 
 
Depending on the symptoms exhibited by a person in each of the tables 
previously mentioned, different presentations either combined, pre-dominantly 
inattentive, or pre-dominantly hyperactive-impulsivity of ADHD is diagnosed. A 
combined presentation involves having enough of the required symptoms from both the 
inattention and hyperactivity and impulsivity criteria. Predominantly inattentive 
presentation includes exhibiting symptoms in the inattentive category and none in the 
hyperactivity and impulsivity, and the inverse is identified in a predominantly 
hyperactive and impulsive presentation in which the person displays only those distinct 
characteristics. For each of the presentations mentioned previously a patient must exhibit 
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the symptoms of the classification for a minimum and continuous time span of 6 months 
(Symptoms and Diagnosis).  
The symptoms listed in Table 1 and 2 come from an observational and recorded 
account by either the patient or a guardian or peer, and subject to personal interpretation. 
Clinicians and therapists alike have a variety of means to assess ADHD in a person, 
including using a computerized assessment called the Pediatric Attention Disorders 
Diagnostic Screener (PADDS), Continuous Performance Tests or CPTs, and Behavior 
Rating Inventory of Executive Function (BRIEF). Two examples of commonly accepted 
CPTs include the Test of Variables of Attention (TOVA) and the Conners’ Continuous 
Performance Test-II (CPT-II). CPT is believed to be successful at screening the executive 
functioning skills of children that might be at a risk for developing ADHD. The CPT also 
is very beneficial for clinicians because it allows them to differentiate a person who has 
ADHD and a reading disorder from a person who only has a reading disorder. A study by 
DeShazo, Grofer, Lyman, Bush, and Hawkins in 2001 analyzed the difference in 
interpreting visual cues and prolonged attention in ADHD diagnosed and un-diagnosed 
children by using the CPT-II. Through the study, they discovered that ADHD children 
had comparable selective attention, exhibited through visual cues, to the un-ADHD 
diagnosed children, but their attention did not sustain for the same amount of time.  
The TOVA screening has been used due to its success in differentiating an ADHD 
child from a non-ADHD child. In early research, the TOVA screen successfully 
identified 80% of those affected and 72% of the controls in the sample, but in the most 
research in 2005, the TOVA was discovered to not be able to distinguish between an 
ADHD child and a child with low levels of behavioral and ADHD problems. Overall, the 
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CPTs have a good positive predictive capacity for ADHD, such as a person performing 
poorly due to having ADHD, but a poor negative predictive capacity, in which doing well 
does not display any results. The results recovered by clinicians through CPTs are 
difficult often to interpret and appropriately assess a patient because ADHD has high co-
morbidities with other disorders and varying levels of actions with each subtype (Reddy, 
Newman, Pedigo, & Scott, 2010).  
 In addition to CPTs, clinicians and therapists utilize the Behavior Rating 
Inventory of Executive Function (BRIEF) screening tool as a first analytical tool to 
evaluate a person’s executive functioning skills, especially in school-aged children. 
Within the BRIEF, there are three aspects involved including a Behavior Regulation 
Index, a Metacognition Index, and a Global Composite. In recent testing and research, it 
has been discovered that the BRIEF testing tool classified ADHD children 82% of the 
time compared to the control, but the tool did not help separate and differentiate between 
those in clinical settings.  
 The Pediatric Attention Disorders Diagnostic Screener (PADDS) is a relatively 
new computerized attention and executive functioning screening tool. It implements 
Target Tests of Executive Functioning (TTEFs) and requires a person to engage in and 
complete three brief computer tasks. The testing and task set-up provided by the PADDS 
allows clinicians to more thoroughly assess executive functioning in children than the 
CPTs (Reddy, Newman, Pedigo, & Scott, 2010).  
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ADHD Treatment 
   Once a child is diagnosed with ADHD, the child and his or her family can 
choose to undergo both or either medicinal or cognitive behavioral therapy. Through 
research it has been discovered that medicinal therapy alone was more effective at 
treatment than behavioral therapy in managing ADHD, but using these two modes of 
therapy together was more effective than using the solely medicinal or behavioral 
therapy. In 2007, about 2.7 million children from the age of 4-17 were using medicinal 
therapy for his or her ADHD treatment plan.  
 In order for the best of outcomes for a child with ADHD, Cognitive Behavioral 
Therapy (CBT) should be used in addition to medicinal therapy. Cognitive behavioral 
therapy works by helping the child to control their impulsivity and redirect it into a more 
positive alternative behavior (McCarthy). Through the analysis of the child’s behavior 
and thoughts, this type of therapy helps break down the child’s challenges and overcome 
their negative thoughts. Implementing this therapy works through praising or giving 
presents to the child as a reward for acting and responding appropriately. This praise and 
reward is aimed to encourage the child to calm down enough to deal with school or other 
challenges he or she might face. Typical Cognitive Behavioral Therapy takes about 12 
weeks of sessions, but several have gone on for as long as nine months. CBT is practical 
and crafted in order to allow the child to be able to develop and learn new skills. The key 
to effective CBT is having a certified, through the Association for Behavioral and 
Cognitive Therapies, and qualified therapist (Shute, 2010).  
 Behavior therapy works by not only improving the skills of the child with ADHD 
but also the parents’. The parents are equipped with better behavior techniques to help 
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them in their parenting of the child. This cooperation between parent and child creates an 
encouraging environment for the child to grow and develop skills in order to improve 
their ADHD symptoms. Psychologists with the American Psychological Association 
recommend that this form of treatment should be the first option for children under the 
age of five. Dr. William Pelham, Ph.D., director of the Center for Children and Families 
at the State University of New York, strongly encourages that children of all ages try this 
form of therapy before seeking medicinal therapy. Pelham explains that there is clear 
evidence that behavioral therapy will be effective for a majority of children, and if the 
child needs to be placed on medicinal therapy later in treatment, the child tends to receive 
a lower dose. Behavioral therapy, however, does take a lot of time and effort for the both 
the parent and child involved. The parent and child could work and be actively following 
the treatment plan and not see results until several weeks or months after beginning. This 
treatment plan is very intense for the parent and child because it requires that they both 
change the ways in which they behave and act and they have to continue these changes 
over time in order for the therapy to be effective (McCarthy).  
 The results from following a behavioral therapy treatment plan are long lasting 
and help the child to grow and develop important skills for him or her to function in 
everyday life. These results are not found, however, when a child undergoes medicinal 
therapy. If a child on medicinal therapy discontinues treatment, his or her ADHD 
symptoms can return, even if the patient had been diligently taking the medication for 10 
years. Another downside to medicinal therapy is that if it is implemented first and is 
successful, the patient and his or her parent is less likely to seek behavioral therapy to 
improve or eliminate the ADHD symptoms completely. Medicinal therapy has 
	 	 	9	
standardized results from drug companies and the medications guarantee an improvement 
almost immediately in ADHD symptoms and manifestations (McCarthy).  
 At the Judge Baker Children’s Center in Boston, an institution geared toward 
treating children with varying psychological, behavior, and social disorders, the 
psychologists and professional personnel seek a behavioral therapy treatment option over 
a more cognitive one. Through a series of published literature on the treatment of ADHD, 
the psychologist at Judge Baker takes the parent of the child through a flow chart of steps 
to helping their child cope and hopefully overcome their symptoms. With each task 
broken down, the parents are given homework to make sure that each action the child 
does is separately and individually rewarded in order for the child to remain focused. At 
this center, personnel from the child’s school is also brought in and encouraged to carry 
over the same actions that the parent does with the child at home. It is a collective effort 
for both the parents and the school to make sure the flow chart treatment method is being 
followed and incorporated throughout the child’s environment. This method of treatment 
is very time consuming for parents and teachers alike, and for single parents the time of 
treatment can be prolonged due to the parent not having the available time to dedicate to 
working with their child. However, regardless of the time required, the treatment laid out 
through the psychologist’s flow chart of behaviors and rewards can help a child to cope 
with and improve their ADHD symptoms. (Interview with Meg Reuland).  
 The Multimodal Treatment Study of Children with Attention Deficit 
Hyperactivity Disorder (MTA) in 1999 analyzed the treatments available for ADHD 
children and whether a combination treatment was more effective than a single treatment 
option. Through this study sponsored by the National Institute of Mental Health, 
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psychologists compared the use of medicinal or behavioral therapy alone to a 
combination therapy in which both methods were used. It was found that three years after 
this study 45-71 percent of the children in the original treatment groups were taking 
medications, but this treatment was not associated with better outcomes after about three 
years. Such a result caused Dr. Peter Jensen to claim “medication can make a long term 
difference for some children if it’s continued with optimal intensity and not started or 
added too late in a child’s clinical course”. In a follow up study, a research team 
evaluated 485 of the children from the original MTA study varying in ages from 10-13. 
Through this study, researchers were able to see that intensive medication management 
alone or in conjunction with behavioral therapy had better outcomes than just behavioral 
therapy or community care alone. Researchers in this study also found that children who 
had intensive behavioral therapy were more likely to begin taking medication, whereas 
those who had been taking medication and then started behavioral therapy were more 
likely to stop. Families and teachers responded to the study and they favored the 
combination of medication and behavioral therapy, and found that such a combination 
allowed for lower medication dosages. The study also revealed that the management of 
medication by an MTA physician instead of a community care source produced better 
outcomes (The MTA Cooperative Group, 1999). 
 This MTA study displayed the aspect, according to Dr. Brooke Molina, that 
ADHD treatment for one year does not prevent serious problems from occurring later. In 
support of such a statement, Brooke Molina and her colleagues found that children with 
ADHD had higher-than-normal rates of delinquency (27.1 vs. 7.4 percent) and substance 
abuse (17.4 vs. 7.8 percent). Through her analysis she also found that the lower amount 
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of substance abuse by children who received intensive behavioral lessened by the third 
year (The MTA Cooperative Group, 1999). 
Medicinal Treatments for ADHD 
In terms of options for medicinal therapy, a patient can be prescribed stimulants, 
or non-stimulants. The choice of stimulants includes Methylphenidate (Concerta, Methyl 
ER, Methylin, Daytrana, Ritalin, Ritalin LA, Ritalin SR, Metadate CD), 
Dextroamphetamine (Dexedrine/Dextrostat, Dextrine Spansule), Lisdexamfetamine 
(Vyvanse), Dexmethylphenidate (Focalin, Focalin XR), and Mixed amphetamine salts 
(Adderall, Adderall XR). Stimulants are the first choice of medication for ADHD patients 
because they are incredibly effective at enhancing the symptoms of ADHD including 
hyperactivity, impulsivity, and inattentiveness. The stimulants work by either inhibiting 
the reuptake of dopamine and norepinephrine, and/or increasing their release to the 
synaptic cleft to inhibit the catabolic or destructive ability of monoamine oxidase. Non-
stimulant medications are often used only if the patient does not see or reach their desired 
results and experiences intense side effects while on stimulant medication. The choice of 
non-stimulants includes Atomoxetine (Strattera), Guanfacine extended-release (Intuniv), 
and Clonidine extended-release (Kapvay).  Atomoxetine works by being a selective 
noradrenergic reuptake inhibitor and inhibits the presynaptic norepinephrine transporter. 
Guanfacine is a specific alpha-2 adrenergic agonist, and Clonidine is a nonspecific alpha-
2 adrenergic agonist. These both function by binding to postsynaptic alpha-2A-
adrenoreceptors in the prefrontal cortex. Through this binding, there is an increase in the 
release of the prefrontal cortex neurons that help control attention, impulse control, and 
other functions that are not well monitored in ADHD.  
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 Side effects with stimulant medication include nausea, vomiting, abdominal pain, 
headache, insomnia, decrease in appetite, and weight loss. In several studies, it has been 
found that stimulants improve mood and irritability. A report by James Swanson and his 
colleagues, based off of the MTA study previously mentioned, confirmed the idea that 
medication slowed growth. In a group of 65 children with ADHD and no medication, 
these children were about three-fourths of an inch taller and six pounds heavier on 
average than a comparative group of 88 children on medication. The growth rates of the 
children in the study, however, normalized after three years (The MTA Cooperative 
Group, 1999). 
Stimulant medications also have a high potential for abuse and may cause 
underlying tics to resurface. Atomoxetine, a non-stimulant medication, can cause nausea, 
vomiting, abdominal pain, headache, somnolence, and decrease in appetite. This 
medication has the potential to increase suicidal thoughts in patients and worsening or 
new psychiatric problems should be reported if they develop while on this medication. 
The other non-stimulant medications, including Guanfacine and Clonidine, have side 
effects that involve headache, insomnia, somnolence, fatigue, abdominal pain, and 
xerostomia. When administering the previously mentioned medications, extra precaution 
should be used to make sure the child does not have a history of cardiovascular disease, 
hypotension, or syncope. If either Guanfacine or Clonidine is discontinued suddenly, 
hypertension could rebound (Lardieri, Morgan, & Vy Nguyen, 2015). 
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Role of the Pharmacist in ADHD Treatment 
  Given the extent of medicinal therapy for children with ADHD, the pharmacist 
plays many roles in helping pediatric patients and their parents manage ADHD treatment. 
A pharmacist should instill the concept of medication adherence to their patients. By 
informing patients of potential side effects, results, and benefits, a pharmacist can provide 
a patient with the incentive to continue to take his or her medication on a regular and 
diligent basis. A pharmacist can also help with medication adherence by encouraging 
patients to have multiple follow-up visits with his or her physician in order to ensure the 
medication is appropriate. Through their knowledge of titrations and dosing formulations 
such as extended-release and transdermal delivery options, a pharmacist can 
accommodate the lifestyles of patients and make it easier for him or her to take their 
medication as prescribed (Manos, Tom-Revzon, Bukstein, & Crimson, 2007).  
 When reviewing and filling prescriptions for ADHD medication therapy, a 
pharmacist should be able to discern whether or not the physician is following the correct 
dosing protocol. When a physician is beginning a patient on such medication, the 
physician should prescribe a dose and then wait. After the initial dose, the physician can 
gradually increase the dose until the ADHD behavior improves. The physician can 
continue to increase the dosage from this point on until side effects begin to appear. Once 
side effects begin to develop, the physician should lower the dose to the original amount 
before the side effects began to be displayed (Manos, Tom-Revzon, Bukstein, & 
Crimson, 2007). 
 For the side effects of reduced appetite, weight loss, and slowed growth, the 
pharmacist should be able to help guide parents in additional steps they can take to 
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reverse or lower such side effects. The pharmacist should monitor the weight, height, and 
body mass index of the patient every six months to make sure there is not a severe gap in 
growth and development. For the loss of appetite side effect, the pharmacist should 
inform the parents to give their child medication after eating and make sure the child has 
high-energy snacks and late night meals if necessary in order to maintain weight. If the 
weight loss and growth are severe, the pharmacist has the ability to question if the dosing 
of the medication should be changed. 
 Children should also be monitored for the potential side effect of high blood 
pressure or heart rate and other cardiovascular problems. Before beginning any of the 
stimulant based medications, the pharmacist should confirm that the child does not have 
any previous history of cardiac problems or genetic risk factors. The pulse and heart rate 
of the patient should also be noted before the child begins treatment. It is crucial that the 
pharmacist informs the patient to seek a physician if his or her heart rate is above 120 
beats per minute or in a state of persistent tachycardia, and the physician can then 
determine if the dosage of the medication should be altered (Lardieri, Morgan, & Vy 
Nguyen, 2015). 
Pharmacists should describe to patients and families how to look for signs and 
risk factors of abuse or misuse of stimulants used for ADHD therapy. If the pharmacist 
observes a patient misusing a drug, the patient should be referred to the clinician. Once 
the patient seeks treatment, the addiction or abusive behavior is treated first and then the 
ADHD symptoms and manifestations will be treated. After treatment, the pharmacist 
should continue to monitor the patient’s use of stimulants, and if there is believed to be a 
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high chance the patient will abuse, a pharmacist should seek to change from a stimulant 
based therapy to an atomoxetine-based option.   
 Pharmacists should inform patients and their parents about the potential side 
effects of ADHD medications and encourage such patients and their parents to keep their 
physician up to date on the progress of their symptoms and any improvements or setbacks 
he or she might experience from the medication. Because the pharmacist sees the patient 
on a more regular basis than a physician, the pharmacist should observe the patient for 
side effects and report such observations to the physician in case the course of treatment 
should be changed. The pharmacist should work with the physician to make sure the 
medication therapy is appropriate and necessary for the patient (Lardieri, Morgan, & Vy 
Nguyen, 2015). 
Community Pharmacists’ Familiarity, Knowledge, Counseling Confidence, and 
Perceptions 
 
 Because community pharmacists play such a key role in ADHD treatment, it is 
important to know pharmacists’ 1) familiarity with ADHD, 2) knowledge of ADHD, 3) 
confidence in counseling children and families with ADHD, and 4) perceptions of 
ADHD. Any lack of familiarity, knowledge, confidence or misperceptions may need to 
be addressed through pharmacist education to fully optimize a patient’s medicinal 
therapy for ADHD. Unfortunately, there is a lack of literature to inform these issues, and 
the literature available is outdated and has not resulted in positive findings. 
A study conducted in 2008 by Ghanizadeh reported that pharmacists lack 
knowledge about ADHD treatments. Through a self-reported questionnaire, pharmacists 
were surveyed on their knowledge and perceptions of Ritalin use for ADHD. Among the 
results, a majority of pharmacists, about 91%, believed that ADHD misbehavior was due 
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to children refusing to follow rules and finishing assignments, while only about 40% of 
pharmacists believed ADHD had biological and genetic vulnerabilities and causation. 
With regard to treatment, 85.5% of these pharmacists said that Ritalin is used for 
improving concentration and 80% of them believed it was the best medication option 
available. Surprisingly though, 70% of pharmacists believed that Ritalin should not be 
taken for ADHD, except for in very severe cases.  
This study revealed that there is a rather large gap between the knowledge and 
perception of Ritalin usage in ADHD patients. Through this study, it was discovered that 
only a few pharmacists surveyed had the opportunity to learn about ADHD, and that most 
pharmacists do not have any more knowledge in identifying the characteristics of ADHD 
than teachers in school do. The results of this study displayed the concept that more 
information and educational material, especially in the topic of pharmacology, should be 
provided to pharmacists regarding ADHD treatment (Ghanizadeh, 2008). 
Study Objectives   
 Due to the lack of literature dedicated to pharmacists’ knowledge, familiarity, 
confidence, and perceptions, the objectives of this study are to: 
1. To measure community pharmacists’ familiarity with ADHD and associated 
treatments for children. 
2. To measure community pharmacists’ knowledge with ADHD and associated 
treatments for children. 
3. To measure community pharmacists’ confidence in counseling ADHD patients 
and their families. 
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4. To measure community pharmacists perceptions of ADHD and associated 
treatments for children. 
The secondary objectives of this study were to test for differences in familiarity,  
knowledge, confidence, and perceptions based on type of degree (Bachelor’s Degree in 
Pharmacy versus Doctor of Pharmacy Degree) and type of pharmacy worked in 
(independent pharmacy versus retail chain pharmacy). 
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METHODS 
Design 
 The study objectives were met by employing a descriptive, cross-sectional design. 
Responses were generated using a self-administered survey that was distributed 
electronically to Mississippi pharmacists through Qualtrics Survey Software.  
Sample 
 The study sample consisted of Mississippi-licensed pharmacists who had valid 
email accounts, acquired from the state board of pharmacy on October 7, 2016. The study 
sample was limited to Mississippi-licensed pharmacists who practice in a field in which 
they dispense ADHD medication. Mississippi-licensed pharmacists who work in a clinic, 
hospital, or academic setting were excluded from completing the survey upon answering 
that they worked in a setting that did not dispense ADHD medication. A total of 6,872 
emails were sent to Mississippi-licensed pharmacists.  
Data Collection 
 Prior to sending the survey to Mississippi-licensed pharmacists, an Abbreviated 
IRB Application was submitted to the University of Mississippi IRB for approval to 
begin data collection. The University of Mississippi IRB approved the application as 
exempt under 45 CFR 46.101(b)(#2). The study to be completed by the pharmacists was 
conducted by first using an online survey generated by the Qualtrics Survey Software. 
The survey generated may be found in Appendix A. The link to complete the survey was 
sent to the sample described above in an email that explained both the survey and the 
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purpose of the study. Following the initial sending of the survey, a week later another 
email was sent to those in the sample that had not yet completed the survey. The follow-
up email also contained the link to the survey and a reminder of the purpose of the study. 
The body of the initial and follow-up emails may be found in Appendices B and C.  
 The survey began by asking the primary practice setting of the pharmacist. If the 
participant answered working in a clinic that does not dispense ADHD medications, a 
hospital, or any other setting individually inputted the individual was excluded from the 
rest of the survey. If the participant answered with working in a chain or independent 
community pharmacy or a clinic that dispenses ADHD medication the individual was 
prompted to continue the survey and answer educational and demographic information. 
Questions included age, sex, ethnicity/race, years of practicing pharmacy, pharmacy 
practice job title, pharmacy training/education, and number of weekly prescription 
ADHD dispensing and refills.  
 Following these background questions, the survey developed into questions that 
tested the familiarity of the participant with ADHD symptoms, behaviors, diagnostic 
testing, and medications, including side effects and resources. Based upon the 
individual’s familiarity with a certain aspect of ADHD, the participant was asked to 
indicate by choosing a number 1 through 5 (1 being not at all familiar and 5 being 
extremely familiar).   
 The survey then continued by testing the knowledge of the participants on 
different ADHD medication types, categories, as well as, dispensing protocols and side 
effects. There were also questions to test the knowledge of individuals on ADHD 
preconceptions and statistics. 
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 In the final section of the survey, the participant was asked to indicate their 
confidence in counseling on ADHD medications and voice their opinions or perceptions 
of ADHD medications and prescriptions. Statements regarding counseling asked about 
the individual’s confidence in their ability to inform patients about medication side 
effects and their confidence in dispensing the appropriate medication. Based upon the 
statement made, the individual indicated on a scale of 1 to 5 (1 being strongly disagree 
and 5 being strongly agree) their confidence in the certain situation. This part also asked 
whether participants believed there should be more continuing education courses or 
curriculum in pharmacy school dedicated to ADHD medication therapy.  
 In the perceptions aspect of the survey, individuals were able to agree or disagree 
on a scale of 1 to 5 (1 being strongly disagree, 3 being neither agree nor disagree, and 5 
being strongly agree) whether they believe ADHD diagnosing is on the rise, or if children 
are misdiagnosed or inappropriately treated and not thoroughly informed of their 
condition. 
 The last question was an essay or open-ended question that asked about the 
individual’s final thoughts or additional concerns on the topic of ADHD and the research 
study.  
Analysis 
 
 Sample description. The pharmacist sample was described by calculating 
frequencies, means, and percentages for the demographic characteristics of the 
pharmacist respondents. 
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 Pharmacists’ familiarity. Frequencies and percentages were used to assess the 
familiarity of pharmacist with ADHD symptoms, medications, treatment options, 
screening tools, and resources.  
Pharmacists’ knowledge. Frequencies and percentages were used to describe the 
knowledge of pharmacists on ADHD symptoms in children, drug therapy, and 
medication options.  
 Pharmacists’ confidence. Frequencies and percentages were implemented to 
analyze the confidence of pharmacists in dispensing and counseling ADHD medications 
to patients.  
 Pharmacists’ perceptions. Frequencies and percentages were calculated to assess 
the perceptions of pharmacists on the usage and prescribing of ADHD medications in 
children.  
 Differences testing. To meet the secondary objective of this study, Pearson Chi 
Square tests of Independence were used at a .05 level of significance to test for 
differences in familiarity, knowledge, confidence, and perceptions based on type of 
degree (Bachelor’s Degree in Pharmacy versus Doctor of Pharmacy Degree) and type of 
pharmacy worked in (independent pharmacy versus retail chain pharmacy). 
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RESULTS 
Response Rate 
 Through the Qualtrics Survey Software, 6,782 emails were sent to Mississippi 
Pharmacists and 676 surveys were completed which yielded an initial response rate of 
9.83%.  Through the initial screening questions, however, pharmacists who worked in a 
clinic that did not dispense ADHD medications, a hospital pharmacy, or other setting not 
listed were not qualified to finish the survey and were prompted to the end of the survey. 
Out of the 676 respondents, 368 of them qualified to complete the entire survey. There 
were 48 surveys that were not completed by participants who qualified. As a result, 320 
surveys were used in final data analysis.  
Sample Description 
 Of the 320 respondents, most were female, white/Caucasian, had a Doctor of 
Pharmacy Degree (PharmD) as their most advanced pharmacy training, worked in a retail 
chain setting in a rural area, were staff/employee pharmacists, and did not recall having 
ADHD training in their pharmacy degree program and had not taken a continuing 
education program or other ADHD training after graduation. Table 3 summarizes the 
demographic characteristics of respondents. 
The average age of the 318 participants (2 participants did not answer) was 43.31 
with a standard deviation of 13.45 and the minimum and maximum age of 24 and 81, 
respectively. Of the participating pharmacists, the average years practicing was 17.26 
with a standard deviation of 14.60 and a minimum and maximum of 0 and 58. There were 
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312 respondents reported his or her weekly prescription fill numbers and the average was 
1887.89 with a standard deviation of 1330.00 and a minimum and maximum of 20 and 
8000. Of the 315 responses available regarding ADHD prescription fills in a week, the 
average number was 95.10 with a standard deviation of 188.18 and a minimum and 
maximum of 0 and 2000.  
Table 3: Demographic Characteristics 
Gender Number of Respondents (%) 
     Female  
     Male 
     186 (58.1) 
     134 (41.9) 
Race/Ethnicity Number of Respondents (%) 
     White/Caucasian 
     African American/Black 
     Asian/Indian Asian 
     Hispanic 
     American Indian/Alaskan Native 
     Native Hawaiian/Other Pacific Islander 
     Other 
     278 (86.9) 
     18 (5.6) 
     15 (4.7) 
     3 (0.9) 
     1 (0.3) 
     0 (0) 
     5 (1.6) 
Most Advanced Pharmacy Training Number of Respondents (%) 
     Doctor of Pharmacy (PharmD) 
     Bachelor’s Degree in Pharmacy (BS) 
     Master’s Degree in Pharmacy (MS) 
     Doctor of Philosophy in Pharmacy (PhD) 
     193 (60.3) 
     121 (37.8) 
     3 (0.9) 
     3 (0.9) 
Type of Pharmacy Number of Respondents (%) 
     Retail chain pharmacy 
     Independent pharmacy 
     Clinic that dispenses ADHD medication 
     194 (60.6) 
     122 (38.1) 
     4 (1.3) 
Location of Pharmacy Number of Respondents (%) 
     Rural (less than 50,000 people) 
     Metropolitan (greater than 50,000 people) 
     176 (55) 
     144 (45) 
Job Title Number of Respondents (%) 
     Staff/Employee Pharmacist 
     Manager/Pharmacist in Charge 
     Other 
     161 (50.3) 
     152 (47.5) 
     7 (2.2) 
ADHD Instruction in Pharmacy School Number of Respondents (%) 
     No 
     Yes  
     Maybe 
     163 (50.9) 
     89 (27.8) 
     68 (21.3) 
Continuing Education Program in ADHD Number of Respondents (%) 
     No 
     Yes 
     219 (68.4) 
     101 (31.6) 
	 	 	24	
 
Pharmacists’ Familiarity 
Across all valid responses recorded, pharmacists displayed a slight, moderate, and 
very familiar response pattern. Table 4 below describes in detail respondents’ ratings of 
familiarity for each of the six items. Bolded numbers indicate most frequently chosen 
category for each item. No significant differences in respondents’ familiarity with ADHD 
were found when comparing location of practice (independent pharmacy versus chain 
pharmacy) or level of training (BS vs. PharmD). 
Table 4: Pharmacists’ Familiarity with ADHD 
Please indicate how 
familiar you are with 
each of the following 
statements by selecting 
the one choice which 
best describes your 
familiarity 
Extremely 
Familiar 
Freq. (%) 
Very 
Familiar 
Freq. (%) 
Moderately 
Familiar 
Freq. (%) 
Slightly 
Familiar 
Freq. (%) 
Not 
Familiar 
at All 
Freq. 
(%) 
Symptoms of ADHD 43 (13.4) 102 (31.9) 148 (46.3) 27 (8.4) 0 (0) 
Medications that are 
used to treat ADHD 86 (26.9) 155 (48.4) 73 (22.8) 6 (1.9) 0 (0) 
Side effects from 
medications used to treat 
ADHD 
48 (15) 142 (44.4) 117 (36.6) 13 (4.1) 0 (0) 
Non-pharmacological 
treatments used to 
manage ADHD 
17 (5.3) 38 (11.9) 142 (44.4) 82 (25.6) 41 (12.8) 
Screening tools available 
for ADHD patients 12 (3.8) 32 (10) 92 (28.8) 114 (35.6) 70 (21.9) 
ADHD resources that 
can be used by patients 
and other healthcare 
professionals 
15 (4.7) 26 (8.1) 81 (25.3) 110 (34.4) 88 (27.5) 
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Pharmacists’ Knowledge 
 
 In terms of knowledge on ADHD related symptoms, treatments, and diagnosing, a 
large majority of responding pharmacists were able to correctly recognize all of the 
true/false statements except for statement 2 in which a majority incorrectly answered this 
statement as true (see Table 5, below). Bolded numbers indicate most frequently chosen 
category for each item. Pearson Chi Square tests demonstrated that more PharmD 
respondents answered the true/false statements correctly as true compared to those with a 
BS in statement 1 (Χ2 = 6.26; p ≤ .044) and 4 (Χ2 = 7.73; p ≤ .021) (Figures 1 and 2, 
respectively), but had a higher percentage incorrectly answering true in statement 2 (Χ2 = 
6.56; p ≤ .037) (Figure 3). When tests were run comparing chain and independent 
pharmacists, there was only a difference in responses for statement 6 in which more chain 
pharmacists recognized it correctly as false than independent pharmacists (Χ2 = 9.42; p ≤ 
0.009) (Figure 4). 
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Table 5: Pharmacists’ Knowledge of ADHD 
Please indicate whether 
the following statements 
are True (T) or False (F) 
TRUE 
Freq. (%) 
FALSE 
Freq. (%) 
I Don't Know 
Freq. (%) 
Not 
Answered 
Freq. (%) 
Children with ADHD have 
higher-than-normal rates of 
delinquency and substance 
abuse 
181 (56.6)* 69 (21.6) 70 (21.9) 0 (0) 
Patients have to exhibit 
symptoms of ADHD for a 
minimum of 3 months to be 
diagnosed with ADHD and 
receive treatment 
134 (41.9) 89 (27.8)* 97 (30.3) 0 (0) 
Drug therapy only has to be 
followed by a patient for 10 
years, after which the patient 
will maintain their new non-
ADHD behavior 
6 (1.9) 236 (73.8)* 78 (24.4) 0 (0) 
Stimulant medication has been 
demonstrated to slow growth in 
children 
139 (43.4)* 107 (33.4) 74 (23.1) 0 (0) 
Young girls are more likely to 
be diagnosed with ADHD due to 
hyperactive behaviors than 
young boys 
11 (3.4) 274 (85.6)* 35 (10.9) 0 (0) 
ADHD medications follow a 
proper dosing protocol as 
determined by the physician and 
the dose cannot change even if 
there are side effects 
7 (2.2) 298 (93.1)* 15 (4.7) 0 (0) 
Clonidine and Guanfacine are 
stimulant medications for 
ADHD 
40 (12.5) 270 (84.4)* 10 (3.1) 0 (0) 
Strattera (or Atomoxetine) is a 
selective noradrenergic reuptake 
inhibitor inhibiting the 
presynaptic norepinephrine 
transporter 
255 (79.9)* 22 (6.9) 42 (13.1) 1 (0.3) 
*indicates the correct answer 
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Figure 1: Knowledge Item 1 Responses between BS and PharmD Respondents 
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Figure 2: Knowledge Item 4 Responses between BS and PharmD Respondents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Knowledge Item 2 Responses between BS and PharmD Respondents 
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Figure 4: Knowledge Item 6 Responses between Independent and Retail Chain 
Pharmacists 
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Pharmacists’ Confidence 
A majority of pharmacy respondents agreed with the items addressing confidence 
(Table 6). Bolded numbers indicate most frequently chosen category for each item. No 
significant differences in respondents’ confidence with ADHD were found when 
comparing location of practice (independent pharmacy versus chain pharmacy) or level 
of training (BS vs. PharmD). 
Table 6: Pharmacists’ Confidence with ADHD* 
Please indicate the 
extent to which 
you agree with 
each of the 
following 
statements by 
selecting the one 
option which best 
describes your 
opinion 
Strongly 
Disagree 
Freq. 
(%) 
Disagree 
Freq. 
(%) 
Somewhat 
Disagree 
Freq. (%) 
Neither 
Agree or 
Disagree 
Freq. 
(%) 
Somewhat 
Agree 
Freq. (%) 
Agree 
Freq. 
(%) 
Strongly 
Agree 
Freq. 
(%) 
I feel confident in 
my ability to 
counsel patients 
about the 
medication profile 
and side effects of 
medications being 
used for the 
treatment of 
ADHD 
7 (2.2) 6 (1.9) 16 (5.0) 16 (5.0) 116 (36.6) 
120 
(37.9) 
36 
(11.4) 
I feel comfortable 
dispensing 
medications used 
in the treatment of 
ADHD 
10 (3.2) 8 (2.5) 18 (5.7) 10 (3.2) 62 (19.6) 155 (48.9) 
54 
(17.0) 
I feel that I could 
benefit from taking 
a continuing 
education or 
training program in 
the area of ADHD 
10 (3.1) 2 (0.2) 2 (0.2) 13 (4.1) 27 (8.5) 142 (44.8) 
121 
(38.2) 
I feel that 
pharmacy school 
curricula should 
include instruction 
in the area of 
ADHD 
5 (1.6) 5 (1.6) 4 (1.3) 15 (4.7) 33 (10.4) 148 (46.7) 
107 
(33.8) 
*Three respondents did not complete this section of the survey 
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Pharmacists’ Perceptions 
A majority of pharmacy respondents agreed or strongly agreed with perception 
items (Table 7). Bolded numbers indicate most frequently chosen category for each item. 
The second perception item, “I feel some doctors or physicians are more inclined than 
others to write a prescription for ADHD medications for children” was different between 
participants with a BS and a PharmD degree (Χ2 = 14.20; p ≤ 0.014). More PharmD 
participants “neither agree nor disagree” and “strongly agree” than those participants with 
a BS degree (Figure 5). 
Table 7: Pharmacists’ Perceptions of ADHD* 
Please indicate the 
extent to which you 
agree with each of 
the following 
statements by 
selecting the one 
option which best 
describes your 
opinion 
Strongly 
Disagree 
Freq. 
(%) 
Disagree 
Freq. 
(%) 
Somewhat 
Disagree 
Freq. (%) 
Neither 
Agree or 
Disagree 
Freq. 
(%) 
Somewhat 
Agree 
Freq. (%) 
Agree 
Freq. 
(%) 
Strongly 
Agree 
Freq. 
(%) 
I feel there has been 
a rise in ADHD 
medication usage by 
children under the 
age of 12 
3 (1.0) 2 (0.6) 2 (0.6) 16 (5.1) 17 (5.4) 115 (36.5) 
160 
(50.8) 
I feel some doctors 
or physicians are 
more inclined than 
others to write a 
prescription for 
ADHD medications 
for children 
4 (1.3) 3 (1.0) 1 (0.3) 16 (5.1) 26 (8.3) 119 (37.8) 
146 
(46.3) 
I feel many children 
are inappropriately 
diagnosed with 
ADHD 
2 (0.6) 10 (3.2) 5 (1.6) 19 (6.0) 66 (21.0) 108 (34.3) 
105 
(33.3) 
I feel that physicians 
and doctors fail to 
emphasize 
behavioral therapy 
in addition to 
medication therapy 
1 (0.3) 3 (1.0) 8 (2.5) 26 (8.3) 37 (11.7) 120 (38.1) 
120 
(38.1) 
*Five respondents did not complete this section of the survey 
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Figure 5: Perception Item 2 Responses between BS and PharmD Respondents 
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DISCUSSION 
This study’s overarching goal was to determine Mississippi’s familiarity, 
knowledge, confidence, and perceptions of ADHD and its treatments. The secondary 
objective was to discern whether there was a difference in these areas between 
independent and chain community pharmacists, as well as, between pharmacists with a 
BS degree versus a PharmD.  
Familiarity 
Across all valid responses recorded, pharmacists displayed a slight, moderate, and 
very familiar response pattern which indicates that pharmacists currently practicing have 
a good concept and working comfort with dispensing ADHD medications and counseling 
on side effects, treatment options, and other resources available. Not surprisingly, 
pharmacists reported their highest levels of familiarity with the items, “medications that 
are used to treat ADHD” and “side effects from medications used to treat ADHD”. Self-
reported familiarity appeared to lessen when assessing items less related to 
pharmacological therapies, suggesting that pharmacists are less familiar with these areas 
of ADHD diagnosis and treatment. Therefore, there may be some value in continuing 
education (CE) for pharmacists that focuses on symptoms, non-pharmacological 
treatments, screening tools and ADHD resources in addition to CE that focuses on 
medicinal treatment. Some respondents did convey related comments at the end of their 
survey. One respondent said, “Instruction from pharmacy school other than teach 
yourself would be helpful but a ce would be great for ongoing information.” Another 
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respondent indicated, “If there are any current ADHD/ADD CE available please send the 
links.” 
Pharmacists’ Knowledge  
 In terms of knowledge on ADHD related symptoms, treatments, and diagnosing, a 
large majority of responding pharmacists were able to correctly recognize all of the 
true/false statements except for the statement, “Patients have to exhibit symptoms of 
ADHD for a minimum of 3 months to be diagnosed with ADHD and receive treatment.” 
For this item, a majority incorrectly answered this statement as true. Additionally, more 
respondents indicated, “I don’t know” for this statement than any other statement. This 
may have been due to the specificity of the item with regard to diagnosis of ADHD, 
which is not an area a pharmacist would likely have advanced training in. Not 
surprisingly, pharmacists again performed well with items that pertained to drug 
treatments. These were also items where an answer of “I don’t know” was seen least 
frequently.  
Significantly more PharmD respondents answered the statements, “Children with 
ADHD have higher than normal rates of delinquency and substance abuse” and 
“Stimulant medication has been demonstrated to slow growth in children” correctly to be 
true compared to those with a BS as their highest degree. While it is difficult to explain 
why more PharmD graduates than BS graduates answered the first item above correctly 
to be true, it may be that they answered the second item above to be true due to more 
advanced clinical training. Interestingly, these same PharmD respondents had a higher 
percentage incorrectly answering true for the statement, “Patients have to exhibit 
symptoms of ADHD for a minimum of 3 months to be diagnosed with ADHD and 
	 	 	35	
receive treatment. It would have been expected to see an opposite trend given the more 
extensive clinical training of PharmD graduates. However, when it comes to the area of 
diagnosis in ADHD, this may be an area all pharmacist struggle with due to lack of 
training in this area. As previously described, this might be a helpful area of instruction 
for pharmacists’ CE.  
When responses from chain and independent pharmacists were compared, there 
was only a difference in responses for the statement, “ADHD medications follow a 
proper dosing protocol as determined by the physician and the dose cannot change even if 
there are side effects,” in which more chain pharmacists recognized it correctly as false as 
independent pharmacists. Perhaps it is possible that chain pharmacists, due to higher 
prescription volumes, have more experience in seeing dosing protocols for ADHD and 
watching those protocols change and symptoms are experienced by the patient.  
Confidence 
A majority of pharmacy respondents agreed with the items addressing confidence 
as it relates to counseling patients and dispensing ADHD medications. At the same time, 
respondents did indicate a need for additional education in the form of CE or more 
instruction in pharmacy school. No significant differences in respondents’ confidence 
with ADHD were found when comparing location of practice (independent pharmacy 
versus chain pharmacy) or level of training (BS vs. PharmD). One respondent did 
indicate at the end of the survey that they “Often feel somewhat inadequate in counseling 
parents on treatment options” 
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Perceptions 
A majority of pharmacy respondents agreed or strongly agreed with perception 
items: “I feel there has been a rise in ADHD medication usage by children under the age 
of 12”, “I feel some doctors or physicians are more inclined than others to write a 
prescription for ADHD medications for children”, “I feel many children are 
inappropriately diagnosed with ADHD”, “I feel that physicians and doctors fail to 
emphasize behavioral therapy in addition to medication therapy”. The second perception 
item, “I feel some doctors or physicians are more inclined than others to write a 
prescription for ADHD medications for children” resulted in significantly different 
responses between participants with a BS and a PharmD degree. More PharmD 
participants “neither agree nor disagree” and “strongly agree” than those participants with 
a BS degree. Overall, pharmacists appeared to agree that there is an emphasis on 
medication therapy for the treatment of ADHD. However, pharmacists may be certainly 
biased toward this view given that there primary exposure of ADHD patients is in the 
pharmacy whereby patients are receiving medications. At the end of the survey, some 
respondents did provide comments suggesting that overprescribing for ADHD, especially 
stimulants may be an issue. 
“Over the past 5 years there has been a MASSIVE increase in the number of 
stimulant prescriptions for both adults and children. I see a lot of NPs writing for 
stimulants now in the course of general/family practice. Stimulants are the go to 
drugs. I rarely ever dispense clonidine or Guanfacine. Despite being CIIs I don't 
think patients or providers exercise enough caution regarding the addictive nature 
of the drugs or the potential for side effects. Pharmacists are caught in the middle. 
The current situation reminds me of the early days of the opioid use epidemic that 
the entire country is struggling with now.” 
 
“In my opinion, there are children who are both misdiagnosed with ADHD and 
under diagnosed with ADHD. Parents and physicians are sometimes too eager to 
prescribe medications based on the child's behavior rather than looking at the 
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entire picture. Many children are prescribed ADHD medications to "control" or 
"calm" the child when behavior modification is all that is needed. Medicating the 
child is the easy way out and requires less effort on all those involved. Basically, 
doctors are allowing parents who should perhaps be better at parenting the easy 
way out by drugging up these kids. On the other hand because these medications 
are over-prescribed, those physicians who should diagnose and prescribe ADHD 
medications for those who truly have ADHD do not prescribe medications for 
those who would truly benefit. Fear of over-prescribing has dictated how many of 
the physicians treat those with ADHD.” 
“When I graduated I was instructed that the dispensing of these C-2 narcotics to 
children would have been considered highly unethical. Further, we were taught 
that by definition, these c-2 medications are highly addictive and any drugs in this 
category could only be used long term, ethically, for terminal illnesses or very 
rare unbearable pain situations (i.e. tragic car accident). There is an unprecedented 
drug epidemic in society which is significantly contributed to by the grossly 
inadequate education and training of health care professionals by educational 
institutions.”  
 
“I also feel that the early, constant and even high doses of amphetamine based 
stimulants is a roadmap for future psychological abnormalities.ie (Depression, 
Anger, Schizophrenia). I feel that non-amphetamine based treatment protocols 
along with tedious behavioral modification therapy should be used as first-line 
treatment.” 
 
“We need long-term data about the effects of stimulant use over extended periods 
of time on brain development and function. We need data about abuse of adhd 
meds by the adult population (college students, healthcare providers, etc.).” 
 
“By not doing proper diagnosing of ADHD our children are at the risk of 
depending on these potent drugs and suffer the consequences of the side effects. 
There should be behavioral therapy mandatory before doctors are allowed to start 
patients on ADHD medications.” 
 
“Over the past 10 years, I've worked in 2 different retail chain pharmacies. These 
2 pharmacies are only 10 miles apart, fill approx the same number of scripts, but 
are in 2 very different socioeconomic areas. I was shocked that my pharmacy in 
the wealthier area (a Target pharmacy), with primarily upper middle class 
customers filled probably 10 times the volume of ADHD meds for children AND 
adults. The same also being true for anti-depressant medications which filled our 
"fast-mover" shelves. I was more than a little shocked! We even have entire 
families that are all on ADHD meds. Wayyyy over prescribed in my opinion.” 
 
“In the area in which I practice pharmacy, I see a higher than average number of 
ADHD medications dispensed to children specifically. Although I have received 
positive feedback from parents, I agree both parents and doctors alike are more 
inclined to dispense these medications as opposed to behavioral therapy.” 
	 	 	38	
 
To other pharmacists, overprescribing is not an issue. 
“I believe it is important to discuss the benefits / adverse reactions with parents 
but I strongly believe that physicians are diagnosing and prescribing very well.  I 
am ADD and strongly favor the benefits of properly-prescribed medications.” 
 
“We are dispensing 1/4 of the number of ADHD prescriptions now versus a 
decade ago.  I don't know why, but we have relatively few rx's for children for 
ADHD.” 
 
Limitations 
There are several limitations to this study that need to be considered when 
interpreting the results. It should be clear that the items in this survey, although 
developed from a literature review, have not been validated. This survey was 
administered in a small local sample of pharmacists therefore the results are not 
generalizable to a broader population of pharmacists outside of Mississippi. Finally, some 
social desirability bias is expected in a survey that is assessing areas like familiarity, 
knowledge, confidence, and perceptions. 
Conclusions 
The results of this study demonstrate that Mississippi pharmacists are generally 
knowledgeable and comfortable in their role as dispensers of ADHD medications for 
children and also in counseling patients and families about those medications. However, 
there still appears to be some need for supplemental education in the form of CE or 
enhanced pharmacy school education to reinforce pharmacists’ knowledge about 
pharmacological treatments. Pharmacists were less knowledgeable and familiar with 
diagnosis of ADHD and non-pharmacological treatments, which is expected given their 
practice area. The question to be asked is whether education for pharmacists in these 
latter areas is necessary, especially if they are not specialists in ADHD. It can be argued 
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that pharmacists would benefit from training in ADHD outside of pharmacological 
treatments. As the most accessible healthcare professional, pharmacists are likely to be 
called on by families of patients with ADHD for guidance. Additionally, a collaborative 
healthcare team approach should be taken between doctor, pharmacist, and therapist to 
ensure the patient’s ADHD is not only being handled through medication therapy, but 
through a holistic approach. Indeed, it appeared that there was some concern among 
respondents that there may exist some over-reliance on pharmacological therapies. Future 
studies should analyze physician-prescribing patterns for children with ADHD and 
explore the collaborative relationship between physicians and pharmacists who care for 
children with ADHD. By working in a cooperative and interactive team between doctor, 
pharmacist, and therapist, the treatment course and outcome for ADHD children can be 
improved upon and provide life-changing results that empower children. 
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Appendix B: Pharmacist Invitation Letter 
 
Dear Mississippi Pharmacist: 
 
My name is Anna Crider, I am a PY1 pharmacy student at the University of Mississippi I 
am interested in understanding your perceptions and knowledge on the condition of 
ADHD in children. This project is being conducted as part of my honor’s thesis 
requirement. Your participation in this survey is vital in order to determine whether 
pharmacists are properly equipped with the right information and experience to dispense 
ADHD medications appropriately.   
 
This study has been reviewed by The University of Mississippi’s Institutional Review 
Board (IRB). The IRB has determined that this study fulfills the human research subject 
protections obligations required by state and federal law and University policies. If you 
have any questions, concerns or reports regarding your rights as a participant of research, 
please contact the IRB at (662) 915-7482.  For specific questions about this research 
project, please call Erin Holmes at 662-915-5914. Completion of this survey is voluntary 
and your responses will be anonymous. 
 
We have provided the direct link to our survey below.  It should take no more than 5 
minutes to complete.  In the event that you are unable to complete the instrument in one 
sitting, you may return to the incomplete instrument using the link provided below, which 
allows you to return to the last prompt attempted.  Each and every survey completed and 
returned helps to ensure we get an accurate assessment of pharmacists’ knowledge and 
opinions.  
 
Your participation and support in this study is greatly appreciated. 
 
Sincerely, 
    
Anna Crider 
PY1 Pharmacy Student 
University of Mississippi School of Pharmacy 
 
Erin Holmes, PharmD, PhD 
Assistant Professor of Pharmacy Administration 
University of Mississippi School of Pharmacy 
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Appendix C: Pharmacist Reminder Letter 
 
Dear Mississippi Pharmacist: 
 
About a week ago you should have received a questionnaire by email asking about your 
perceptions and knowledge on the condition of ADHD in children. If you have already 
completed it, please disregard this letter-we thank you for your response.  If you haven’t, 
we hope you will consider completing it because each and every survey completed helps 
to ensure we get an accurate assessment of pharmacists’ opinions.  The survey (link 
provided below) should take no more than 5 minutes to complete.   
 
As a current pharmacy student at the University of Mississippi, I am interested in 
understanding the Mississippi pharmacist community’s perspective on ADHD 
medications prescribed for children.  This project is being conducted as part of my 
honor’s thesis requirement. 
 
This study has been reviewed by The University of Mississippi’s Institutional Review 
Board (IRB). The IRB has determined that this study fulfills the human research subject 
protections obligations required by state and federal law and University policies. If you 
have any questions, concerns or reports regarding your rights as a participant of research, 
please contact the IRB at (662) 915-7482. 
 
We have provided the direct link to our survey below.  In the event that you are unable to 
complete the instrument in one sitting, you may return to the incomplete instrument using 
the link provided below, which allows you to return to the last prompt attempted.  Each 
and every survey completed and returned helps to ensure we get an accurate assessment 
of pharmacists’ opinions. 
 
Sincerely, 
 
Anna Crider    
PY1 Pharmacy Student 
University of Mississippi School of Pharmacy 
 
Erin Holmes, PharmD, PhD 
Assistant Professor of Pharmacy Administration 
University of Mississippi School of Pharmacy 
 
 
